We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $144.15 · 13 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 - Business Wire
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 Business Wire
Mirum Pharmaceuticals (MIRM) price target increased by 16.75% to 149.29 - MSN
Mirum Pharmaceuticals (MIRM) price target increased by 16.75% to 149.29 MSN
MIRM Stock Price, Quote & Chart | MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) - ChartMill
MIRM Stock Price, Quote & Chart | MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) ChartMill
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance - Yahoo Finance
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance Yahoo Finance
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | After market close (AMC) | $-0.81 | — | — | $165.44M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.3 | — | — | $111.59M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-1.36 | — | — | $237.47M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-1.06 | — | — | $147.1M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 19. | Wolfe Research | — | Initiate coverage | — → Outperform | — | Wolfe Research: Outperform |
| 2026. 05. 08. | TD Cowen | — | Maintain | Buy → Buy | — | TD Cowen: Buy |
| 2026. 05. 08. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 05. 07. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 05. 07. | Baird | — | Maintain | Outperform → Outperform | — | Baird: Outperform |
| 2026. 05. 06. | Morgan Stanley | — | Maintain | Overweight → Overweight | — | Morgan Stanley: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 774,841 | $71.58B | 0.06% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 346,991 | $32.06B | 0.06% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 388,542 | $30.69B | 0.05% | — | New position |
| 4 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 190,638 | $15.06B | 0.02% | — | New position |